FDA halts use of Regeneron, other monoclonal antibody COVID treatment, DeSantis says move ‘reckless’
Wednesday, January 26, 2022 | Tag Cloud Tags: covid-19, EU, News, Trump, virus, Washington, Worthy News | Learn about our FREE SYNDICATION Service | Sign up for our Worthy Briefs! | Printer Friendly
(Worthy News) – The Food and Drug Administration has removed two monoclonal antibody therapies from its list of COVID-19 treatments, saying they should not be used in the U.S. because of their ineffectiveness against the virus’ now-dominant Omicron variant.
The agency’s announcement Monday was followed by the Department of Health and Human Services stopping, at least for now, the distribution of the antibody medications made by Regeneron Pharmaceuticals and Eli Lilly, according to The Washington Post.
Regeneron became well known in November 2020 after President Trump received it to treat his COVID infection while the drug was still in early clinical trials and praised its effectiveness. [ Source: Just the News (Read More…) ]
Latest Worthy News
U.S. Sends Nimitz, Destroyers, and Refueling Fleet Toward Middle East as Israel-Iran War Intensifies
Fair Use Notice:This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner.